Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

Figure 2

Immunohistochemical staining of pretreatment tumour tissues. A. high stathmin H-score (2/300). B. low stathmin H-score (210/300). C. high pS6 H-score (0/300). D. low pS6 H-score (270/300). E. high pMTOR H-score (3/300). F. low pMTOR H-score (105/300). G. high p-AKT H-score (5/300). H. low p-AKT H-score (240/300).

Back to article page